Newsbenzinga
Candel Therapeutics Announces Immunological Biomarker Data From Ongoing Phase 2 Prtk05 Trial In Patients With Intermediate-Risk Localized Prostate Cancer
· Published
Article summary
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…